Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.
On Wednesday, investors got exactly the message they were hoping for from the Federal Reserve, with a minor reduction in bond-buying activity more than offset by promises to keep short-term interest rates low for a longer period than previously expected. Gains ran rampant throughout the stock market, but near the top of the leaderboard were Halozyme Therapeutics , Omeros , and Fluidigm .
Halozyme gained 17% after the company said last night that it was replacing outgoing CEO Gregory Frost with incoming chief executive Helen Torley. With Frost going to Intrexon, it was essential for the enzyme-producing company to make a smooth transition, and Torley's past experience at companies like Onyx Pharmaceuticals reassured investors that she should be up to the task. Halozyme has soared since the beginning of the year as major players in the pharma space hope to use its innovation to allow intravenous drugs to be administered subcutaneously, and making the most of that potential will be Torley's primary mission starting out.
Omeros rose 18% as investors celebrated a decision from the FDA to grant orphan-drug status to the biopharmaceutical company's OMS721 treatment. With the human monoclonal antibody seeking to treat a disorder that can cause brain and kidney clots, Omeros hopes to move into phase 2 trials within the next quarter. With its OMS824 Huntington's Disease treatment already having received orphan-drug designation, Omeros is looking to tap the profit potential from treating rare diseases while also benefiting from an accelerated approval process and other benefits.
Fluidigm jumped 14% after an analyst raised its price target on the stock from $33 to $42 per share. Maxim Group cited the company's potential to grow at a 20% annual rate over the next three years, with its microfluidic systems becoming increasingly useful in the health-care field. With products like its C1 Single-Cell Auto Prep System for genetic analysis, Fluidigm is at the cutting edge of a key area in genetics that could produce huge opportunities in the future.
Get the growth you want to see in your stocks
Don't settle for lagging stocks in your portfolio. Motley Fool co-founder David Gardner, founder of the world's No. 1 growth-stock newsletter, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth-stock superstars, with you! It's a special 100% free report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains, and click here for instant access to a whole new game plan of stock picks to help power your portfolio.
The article Why Halozyme Therapeutics Inc., Omeros Corp., and Fluidigm Corp. Jumped Today originally appeared on Fool.com.Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.